The sigma-2 receptor modulator and investigational therapeutic CT1812 is neuroprotective against 4-HNE-induced cell death in a disease-relevant neuronal model
Wednesday, June 11, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: The investigational therapeutic CT1812, a sigma-2 receptor modulator, has demonstrated neuroprotective properties against 4-HNE-induced cell death in a relevant neuronal model. This research was presented at the Keystone 2025 conference in Whistler, BC, Canada, highlighting its significance in the field. The findings suggest potential therapeutic applications for CT1812 in neurodegenerative diseases.
Price reaction · baseline $0.316 (2025-06-11T14:42:00.000Z) · hit during market hours · 2 other CGTX headline(s) in the window, move may be shared
day 0 close · peak
+0.4%
Market Sentiment Analysis
POSITIVE FACTORS
CT1812 shows neuroprotective effects against cell death.
The research is relevant to disease models.
Presentation at a notable conference indicates credibility.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Cho E, Thiel JK, Caggiano AO, et al. The sigma-2 receptor modulator and investigational therapeutic CT1812 is neuroprotective against 4-HNE-induced cell death in a disease-relevant neuronal model . Poster presented at Keystone 2025 ; Whistler, BC, Canada
Frequently Asked Questions
What is CT1812?
CT1812 is an investigational therapeutic that modulates the sigma-2 receptor.
What does CT1812 protect against?
CT1812 has shown neuroprotective effects against 4-HNE-induced cell death.
Where was the research on CT1812 presented?
The research was presented at the Keystone 2025 conference in Whistler, BC.
What is the significance of this research?
The findings suggest potential therapeutic applications for CT1812 in neurodegenerative diseases.